山东大学耳鼻喉眼学报 ›› 2020, Vol. 34 ›› Issue (6): 123-128.doi: 10.6040/j.issn.1673-3770.0.2020.031

• • 上一篇    下一篇

高迁移率族蛋白B1与变应性鼻炎的相关性

朱正茹综述张小兵审校   

  1. 兰州大学第一医院 耳鼻喉头颈外科, 甘肃 兰州 730000
  • 发布日期:2021-01-11
  • 通讯作者: 张小兵. E-mail:790736924@qq.com

Correlation between high-mobility group box-1 and allergic rhinitis

ZHU ZhengruOveriew,ZHANG XiaobingGuidance   

  1. Department of Otorhinolaryngology & Head and Neck Surgery, the First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China
  • Published:2021-01-11

摘要: 变应性鼻炎(AR)是IgE介导的鼻黏膜的非感染性炎性疾病,其特征是炎症介质的上调和鼻黏膜的炎症细胞浸润。HMGB1作为典型的警报蛋白和损伤相关模式分子,在介导炎症反应、细胞迁移、组织侵袭等中起着多种作用。目前关于HMGB1与变应性疾病的研究主要集中在系统性红斑狼疮、哮喘、特应性皮炎中,对于其在AR中的作用尚有争议,论文就近年来有关学者对HMGB1在AR发病机制中的相关研究进行总结。

关键词: 高迁移率族蛋白B1, 变应性鼻炎, 发病机制, 炎症, 受体, 信号通路

Abstract: Allergic rhinitis(AR)is a noninfectious inflammatory disease of the nasal mucosa mediated by IgE and characterized by the upregulation of inflammatory mediators and infiltration of inflammatory cells in the nasal mucosa. As a typical warning protein and damage-related model molecule, high-mobility group box-1(HMGB1)plays a variety of roles in mediating inflammatory response, cell migration, and tissue invasion. Currently, studies on HMGB1 and allergic diseases mainly focus on systemic lupus erythematosus, asthma, and atopic dermatitis, whereas the role of HMGB1 in AR is still controversial. This article summarizes the relevant researches on the role of HMGB1 in the pathogenesis of AR.

Key words: High mobility group box-1, Allergic rhinitis, Pathogenesis, Inflammation, Receptor, Signal pathway

中图分类号: 

  • R765.21
[1] 程雷, 钱俊俊, 田慧琴. 变应性鼻炎研究的若干进展[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 1-3. doi:10.6040/j.issn.1673-3770.1.2017.021. CHENG Lei, QIAN Junjun, TIAN Huiqin. Research progresses on allergic rhinitis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2017, 31(3): 1-3. doi:10.6040/j.issn.1673-3770.1.2017.021.
[2] Andersson U, Yang H, Harris H. Extracellular HMGB1 as a therapeutic target in inflammatory diseases[J]. Expert Opin Ther Targets, 2018, 22(3): 263-277. doi:10.1080/14728222.2018.1439924.
[3] Fritz G. RAGE: a single receptor fits multiple ligands[J]. Trends Biochem Sci, 2011, 36(12): 625-632. doi:10.1016/j.tibs.2011.08.008.
[4] Ullah MA, Loh Z, Gan WJ, et al. Receptor for advanced glycation end products and its ligand high-mobility group box-1 mediate allergic airway sensitization and airway inflammation[J]. J Allergy Clin Immunol, 2014, 134(2): 440-450. doi:10.1016/j.jaci.2013.12.1035.
[5] Huang WF, Zhao HJ, Dong HM, et al. High-mobility group box 1 impairs airway epithelial barrier function through the activation of the RAGE/ERK pathway[J]. Int J Mol Med, 2016, 37(5): 1189-1198. doi:10.3892/ijmm.2016.2537.
[6] Zhu XW, Cong JN, Yang B, et al. Association analysis of high-mobility group box-1 protein 1(HMGB1)/toll-like receptor(TLR)4 with nasal interleukins in allergic rhinitis patients[J]. Cytokine, 2020, 126: 154880. doi:10.1016/j.cyto.2019.154880.
[7] Yuan Y, Liu Q, Zhao J, et al. SIRT1 attenuates murine allergic rhinitis by downregulated HMGB 1/TLR4 pathway[J]. Scand J Immunol, 2018, 87(6): e12667. doi:10.1111/sji.12667.
[8] Tang HP, Li TT, Han XL, et al. TLR4 antagonist ameliorates combined allergic rhinitis and asthma syndrome(CARAS)by reducing inflammatory monocytes infiltration in mice model[J]. Int Immunopharmacol, 2019, 73: 254-260. doi:10.1016/j.intimp.2019.05.021.
[9] Shimizu S, Kouzaki H, Kato T, et al. HMGB1-TLR4 signaling contributes to the secretion of interleukin 6 and interleukin 8 by nasal epithelial cells[J]. Am J Rhinol Allergy, 2016, 30(3): 167-172. doi:10.2500/ajra.2016.30.4300.
[10] Jiang Huanhuan, Duan Junyan, Xu Kaihong, et al. Resveratrol protects against asthma-induced airway inflammation and remodeling by inhibiting the HMGB1/TLR4/NF-κB pathway[J]. Experimental and therapeutic medicine vol, 2019,18(1): 459-466. doi: 10.3892/etm.2019.7594.
[11] Zhang Han, Yang Nan, Wang Tianyue, et al. Vitamin D reduces inflammatory response in asthmatic mice through HMGB1/TLR4/NFκB signaling pathway[J].Molecular Medicine Reportsvol, 2018, 17(2): 2915-2920. doi: 10.3892/mmr.2017.8216.
[12] 陈删. 高迁移率家族蛋白1在小鼠过敏性鼻炎及急性细菌性鼻窦炎中的表达及其意义[D]. 武汉: 华中科技大学, 2016. CHEN Shan. The role of high mobility group box 1 protein in murine allergic rhinitis and acute bacterial rhinosinusitis[D]. Wuhan: Huazhong University of Science and Technology, 2016.
[13] Liang Y, Hou CC, Kong JL, et al. HMGB1 binding to receptor for advanced glycation end products enhances inflammatory responses of human bronchial epithelial cells by activating p38 MAPK and ERK1/2[J]. Mol Cell Biochem, 2015, 405(1/2): 63-71. doi:10.1007/s11010-015-2396-0.
[14] 徐韶飞, 聂晚频, 姚凯, 等. HMGB1促进血管平滑肌细胞增殖与迁移的机制研究[J]. 中国普通外科杂志, 2015, 24(12): 1703-1708. doi: 10.3978/j.issn.1005-6947.2015.12.013. XU Shaofei, NIE Wanpin, YAO Kai, et al. Mechanism for HMGB1 in promoting migration and proliferation of vascular smooth muscle cells[J]. Chinese Journal of General Surgery, 2015, 24(12): 1703-1708. doi: 10.3978/j.issn.1005-6947.2015.12.013.
[15] 吴欣阳, 朱宏岩, 吴革平. PI3K/PKB通道在肥大细胞介导的过敏性鼻炎中的多重作用[J]. 临床医药文献电子杂志, 2017, 4(72): 14255-14256. doi:10.16281/j.cnki.jocml.2017.72.163.
[16] Zhang YL, You B, Liu XZ, et al. High-mobility group box 1(HMGB1)induces migration of endothelial progenitor cell via receptor for advanced glycation end-products(RAGE)-dependent PI3K/akt/Enos signaling pathway[J]. Med Sci Monit, 2019, 25: 6462-6473. doi:10.12659/MSM.915829.
[17] Lee CC, Lai YT, Chang HT, et al. Inhibition of high-mobility group box 1 in lung reduced airway inflammation and remodeling in a mouse model of chronic asthma[J]. Biochem Pharmacol, 2013, 86(7): 940-949. doi:10.1016/j.bcp.2013.08.003.
[18] Chen YC, Statt S, Wu RE, et al. High mobility group box 1-induced epithelial mesenchymal transition in human airway epithelial cells[J]. Sci Rep, 2016, 6: 18815. doi:10.1038/srep18815.
[19] Kim TH, Lee JY, Lee HM, et al. Remodelling of nasal mucosa in mild and severe persistent allergic rhinitis with special reference to the distribution of collagen, proteoglycans, and lymphatic Vessels[J]. Clin Exp Allergy, 2010, 40(12): 1742-54. doi: 10.1111/j.1365-2222.2010.03612.x.
[20] Cavone L, Cuppari C, Manti S, et al. Increase in the level of proinflammatory cytokine HMGB1 in nasal fluids of patients with rhinitis and its sequestration by glycyrrhizin induces eosinophil cell death[J]. Clin Exp Otorhinolaryngol, 2015, 8(2): 123-128. doi:10.3342/ceo.2015.8.2.123.
[21] 刘阳, 王志斌, 刘争, 等. 高迁移率族蛋白B1在变应性鼻炎中的表达及意义[J]. 中国免疫学杂志, 2010, 26(7): 651-654. LIU Yang, WANG Zhibin, LIU Zheng, et al. doi: CNKI:SUN:ZMXZ.0.2010-07-018. The expression of HMGB1 in nasal mucosa of allergic rhinitis patients and its significance[J]. Chinese Journal of Immunology, 2010, 26(7): 651-654. doi: CNKI:SUN:ZMXZ.0.2010-07-018.
[22] Lu B, Wang C, Wang M, et al. Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review[J]. Expert Rev Clin Immunol, 2014, 10(6): 713-727. doi:10.1586/1744666X.2014.909730.
[23] Pellegrini L, Xue JM, Larson D, et al. HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma[J]. Oncotarget, 2017, 8(14): 22649-22661. doi:10.18632/oncotarget.15152.
[24] Seo MS, Kim HJ, Kim H, et al. Ethyl pyruvate directly attenuates active secretion of HMGB1 in proximal tubular cells via induction of heme oxygenase-1[J]. J Clin Med, 2019, 8(5): E629. doi:10.3390/jcm8050629.
[25] Liu YY, Chen NH, Chang CH, et al. Ethyl pyruvate attenuates ventilation-induced diaphragm dysfunction through high-mobility group box-1 in a murine endotoxaemia model[J]. J Cell Mol Med, 2019, 23(8): 5679-5691. doi:10.1111/jcmm.14478.
[26] Wagner N, Dieteren S, Franz N, et al. Ethyl pyruvate ameliorates hepatic injury following blunt chest trauma and hemorrhagic shock by reducing local inflammation, NF-kappaB activation and HMGB1 release[J]. PLoS One, 2018, 13(2): e0192171. doi:10.1371/journal.pone.0192171.
[27] Chen S, Wang YJ, Gong GQ, et al. Ethyl pyruvate attenuates murine allergic rhinitis partly by decreasing high mobility group box 1 release[J]. Exp Biol Med(Maywood), 2015, 240(11): 1490-1499. doi:10.1177/1535370214566563.
[28] Bhat SM, Massey N, Karriker LA, et al. Ethyl pyruvate reduces organic dust-induced airway inflammation by targeting HMGB1-RAGE signaling[J]. Respir Res, 2019, 20(1): 27. doi:10.1186/s12931-019-0992-3.
[29] Shin JH, Kim ID, Kim SW, et al. Ethyl pyruvate inhibits HMGB1 phosphorylation and release by chelating calcium[J]. Mol Med, 2015, 20: 649-657. doi:10.2119/molmed.2014.00039.
[30] Chen D, Bellussi LM, Cocca S, et al. Glycyrrhetinic acid suppressed hmgb1 release by up-regulation of Sirt6 in nasal inflammation[J]. J Biol Regul Homeost Agents, 2017, 31(2): 269-277.
[31] Bellussi LM, Cocca S, Passali GC, et al. HMGB1 in the pathogenesis of nasal inflammatory diseases and its inhibition as new therapeutic approach: a review from the literature[J]. Int Arch Otorhinolaryngol, 2017, 21(4): 390-398. doi:10.1055/s-0036-1597665.
[1] 朱晶,张睿,赵媛,李炀,樊孟耘,赵昱. 内镜下低温等离子消融治疗不同炎症分期先天性梨状窝瘘45例[J]. 山东大学耳鼻喉眼学报, 2022, 36(5): 24-29.
[2] 马静远, 武天义, 孙占伟, 王卫卫, 李世超, 王广科. 鼻腔鼻窦内翻性乳头状瘤与外周血炎症标志物的相关性研究[J]. 山东大学耳鼻喉眼学报, 2022, 36(4): 35-39.
[3] 敖天, 程雷. 慢性鼻窦炎伴鼻息肉的内型研究及其指导下的精准控制与治疗[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 7-14.
[4] 梁旭,史丽. 慢性鼻窦炎生物靶向药物治疗的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 30-35.
[5] 石帅,郑泉,程雷. 度普利尤单抗在慢性鼻窦炎伴鼻息肉治疗中的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 36-42.
[6] 林海,朱莹,张维天. 慢性鼻窦炎发病中离子通道作用研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 64-70.
[7] 黄丹怡,张婷,陈静,张薇. 上皮屏障在慢性鼻窦炎伴鼻息肉中的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 78-83.
[8] 李佳倪,朱冬冬,孟粹达. 表观遗传学在慢性鼻窦炎伴鼻息肉发病机制中的作用[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 84-91.
[9] 倪璟滋,万文锦,程雷. 变应性鼻炎健康相关生活质量研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 110-115.
[10] 林一杭,李幼瑾. 肠道微生态在儿童变应性鼻炎中的研究现状[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 116-122.
[11] 刘真,宋西成. 细胞焦亡在变应性鼻炎中的作用机制及研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 123-129.
[12] 王娜,柴向斌. 前列腺源性ETS因子在哮喘及鼻黏膜炎性疾病中的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 136-141.
[13] 刘一潼,周穗子,邱前辉. NLRP3炎症小体在慢性鼻窦炎和变应性鼻炎中的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 142-146.
[14] 龚霄阳,程雷. 新冠疫情期间基于门诊患者的变应性鼻炎患者比例构成分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 245-255.
[15] 张雅琪,刘慧敏,曹淋曼,王子钰,林旭,李燕萍,薛刚,吴靖芳. MAPK、PI3K-AKT、NF-κB在小鼠过敏性鼻炎中的表达及意义[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 254-259.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 张晗,黄一飞 . 抗角膜移植排斥的研究进展[J]. 山东大学耳鼻喉眼学报, 2006, 20(1): 84 -87 .
[2] 牛善利,柴茂文,李振秀 . 鼻内镜下鼻甲成形术治疗慢性肥厚性鼻炎60例[J]. 山东大学耳鼻喉眼学报, 2006, 20(1): 16 -18 .
[3] 孟庆国,卢永田,范献良 . 杀伤细胞免疫球蛋白样受体基因多态性与鼻咽癌的关联性[J]. 山东大学耳鼻喉眼学报, 2008, 22(3): 196 -199 .
[4] 马玉起,孔祥春 . 先天性双侧下唇窦道1例[J]. 山东大学耳鼻喉眼学报, 2008, 22(3): 199 -199 .
[5] 万俐佳,鲁海涛,姜义道,刘 辉,李 琴,佘腊枝 . 改良腭咽成形术治疗阻塞性睡眠呼吸暂停综合征41例[J]. 山东大学耳鼻喉眼学报, 2008, 22(3): 204 -205 .
[6] 于青青 ,王跃建 . 硬质耳内镜的临床应用进展[J]. 山东大学耳鼻喉眼学报, 2008, 22(3): 222 -224 .
[7] 吉晓滨,邓家德,臧林泉,王 磊,谢 军 . 豚鼠变应性鼻炎模型血清组胺的测定[J]. 山东大学耳鼻喉眼学报, 2008, 22(3): 228 -230 .
[8] 向登,卢永田,孙焕吉 . 鼻内镜下修补脑脊液鼻漏19例并文献复习[J]. 山东大学耳鼻喉眼学报, 2008, 22(3): 234 -236 .
[9] 邱恩惠,李志春,方文旭 . 嗅觉障碍的中西医治疗[J]. 山东大学耳鼻喉眼学报, 2008, 22(3): 253 -257 .
[10] 殷国华,钟 笑 . 激光减容术治疗舌扁桃体肥大的远期疗效[J]. 山东大学耳鼻喉眼学报, 2008, 22(3): 280 -282 .